tiprankstipranks
Avalo Therapeutics (AVTX)
NASDAQ:AVTX
US Market
AVTX
Avalo Therapeutics
RESEARCH TOOLSreports

Avalo Therapeutics (AVTX) Income Statement

1,047 Followers

Avalo Therapeutics Income Statement

Last quarter (Q4 2025), Avalo Therapeutics's total revenue was $59.00K, a decrease of -69.27% from the same quarter last year. In Q4, Avalo Therapeutics's net income was $-13.72M. See Avalo Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 59.00K$ 441.00K$ 1.92M$ 18.05M$ 5.40M
Gross Profit
$ -285.00K$ 807.00K$ 640.00K$ 14.62M$ 3.91M
Operating Expenses
$ 72.98M$ 69.32M$ 27.99M$ 52.06M$ 86.04M
Depreciation and Amortization
$ 344.00K$ 169.00K$ 158.00K$ 166.00K$ 1.66M
EBITDA
$ -72.92M$ -68.34M$ -23.29M$ -37.27M$ -80.48M
Operating Income
$ -72.92M$ -68.51M$ -27.35M$ -37.44M$ -82.13M
Other Income/Expenses
$ -5.17M$ 33.50M$ -4.18M$ -4.19M$ -2.41M
Pretax Income
$ -78.09M$ -35.02M$ -31.53M$ -41.63M$ -84.55M
Net Income
$ -78.26M$ -35.13M$ -31.54M$ -41.66M$ -84.38M
Per Share Metrics
Basic EPS
$ -5.84$ -4.32$ -113.58$ -1.06K$ -2.33K
Diluted EPS
$ -5.84$ -3.26$ -113.58$ -1.06K$ -2.33K
Weighted Average Shares Outstanding
 13.40M 8.13M 277.73K 39.20K 36.19K
Weighted Average Shares Outstanding (Diluted)
 13.40M 10.78M 277.73K 39.20K 36.19K
Currency in USD

Avalo Therapeutics Earnings and Revenue History